XOMA (XOMA) Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a research note released on Friday.

According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “

Other equities research analysts have also issued reports about the company. HC Wainwright set a $49.00 price objective on XOMA and gave the stock a buy rating in a research note on Friday. ValuEngine upgraded XOMA from a sell rating to a hold rating in a research note on Friday. Wedbush reiterated a buy rating and set a $33.00 price objective on shares of XOMA in a research note on Tuesday, December 19th. Finally, TheStreet upgraded XOMA from an e+ rating to a c- rating in a research note on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. XOMA has an average rating of Hold and an average target price of $38.33.

XOMA (NASDAQ XOMA) opened at $23.19 on Friday. The company has a quick ratio of 3.45, a current ratio of 5.96 and a debt-to-equity ratio of 2.52. XOMA has a 52 week low of $5.27 and a 52 week high of $37.25. The firm has a market capitalization of $193.15, a PE ratio of 31.77 and a beta of 3.03.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.19. XOMA had a negative return on equity of 130.44% and a net margin of 27.49%. The firm had revenue of $5.36 million during the quarter, compared to analyst estimates of $4.12 million. research analysts forecast that XOMA will post -0.62 earnings per share for the current year.

A number of large investors have recently bought and sold shares of XOMA. EAM Investors LLC purchased a new stake in XOMA during the 3rd quarter worth approximately $835,000. OxFORD Asset Management LLP purchased a new stake in shares of XOMA in the third quarter valued at approximately $543,000. Bank of Montreal Can purchased a new stake in shares of XOMA in the fourth quarter valued at approximately $138,000. Acadian Asset Management LLC purchased a new stake in shares of XOMA in the fourth quarter valued at approximately $152,000. Finally, IFP Advisors Inc purchased a new stake in shares of XOMA in the fourth quarter valued at approximately $581,000. Institutional investors own 39.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2018/03/12/xoma-xoma-lowered-to-sell-at-zacks-investment-research.html.

About XOMA

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply